Myriad Genetics Q2 2024 Adj. EPS $0.05 Beats $(0.01) Estimate, Sales $211.500M Beat $204.954M Estimate
Author: Benzinga Newsdesk | August 06, 2024 04:54pm
Myriad Genetics (NASDAQ:
MYGN) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.01) by 600 percent. The company reported quarterly sales of $211.500 million which beat the analyst consensus estimate of $204.954 million by 3.19 percent. This is a 15.26 percent increase over sales of $183.500 million the same period last year.
Posted In: MYGN